Table 2. Association between KRAS/BRAF mutational status and clinico-pathological factors in patients with ovarian cancer.
KRAS/BRAF mutation
|
||||
---|---|---|---|---|
Factors | Patients | Negative | Positive | P-value |
FIGO stage | ||||
I, II | 18 | 8 | 10 | <0.001 |
III, IV | 38 | 38 | 2 | |
Grade | ||||
G1 | 9 | 3 | 6 | <0.001 |
G2, G3 | 49 | 43 | 6 | |
Histology | ||||
Serous | 28 | 26 | 2 | 0.014 |
Others | 30 | 20 | 10 | |
Age (years) | ||||
<60 | 35 | 28 | 7 | 0.293 |
⩾60 | 23 | 17 | 6 | |
p-ERK1/2 | ||||
Positive | 27 | 15 | 12 | <0.001 |
Negative | 31 | 31 | 0 |
FIGO, International Federation of Gynecology and Obstetrics; MAPK, mitogen-activated protein kinase; ERKV2, Extracellular signal-regulated protein kinases1/2.